Tom reports and edits European consumer health care industry news and analysis. Leading HBW Insight’s health and wellness coverage in Europe, he has been writing about the sector since 2013. Tom’s main focus is analyzing the strategies of the world's leading consumer healthcare companies, their business performance, plans and product portfolios. He also reports on regulatory topics such as novel foods and prescription-to-OTC switches.
Latest from Tom Gallen
Intensified competition in the dietary supplements market and consumers squeezed by cost-of-living pressures held back sales at Dermapharm's Arkopharma subsidiary in the first half. A leadership change, along with a renewed focus on commercial excellence, is hoped by Dermapharm to turn the business around.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
OTC erectile dysfunction treatment Eroxon has made it to the Nordics through local distributor Navamedic, which has reported strong consumer uptake.
A round-up of the latest global health and wellness moves: Nestlé and Dr Reddy's name JV head; Be-sup hires comms and regulatory director; Ascendis Health appoints interim CFO.
Dietary supplements containing unauthorized novel foods were reported to the European Commission by national regulators on around 40 occasions in the second quarter of 2024.
Germany's Alzchem failed to convince the UK's health claims committee that daily creatine supplementation can contribute to improved cognitive function.